You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

31 search results for: COPD

ERS 2024 | The Role of IL-33 in <b>COPD</b> Patho and Its Impact on Disease Remodeling

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min

Pulmonology

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

<b>COPD</b> and Asthma: What's the Difference and Is There a Link?

interactivity

COPD and Asthma: What's the Difference and Is There a Link?

5 min

Pulmonology

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

ERS 2024 | Perspectives From the Evolving Biologic Landscape in <b>COPD</b>

expert video

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

20 min

Pulmonology

Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.

expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

45 min

Pulmonology

Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies

expert video

Exacerbations Lead to Worsening Lung Function

2 min

Type 2 Inflammation

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

expert video

ERS 2024 | IL-33 A Promising Target

7 min

Pulmonology

Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

14 min

Pulmonology

Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GermanyChange country/region